Reduced Adverse Effects
According to the Food and Drug Administration, adverse drug reactions, or ADRs, are one of the leading causes of mortality and morbidity in the healthcare system, ahead of pulmonary disease, diabetes, accidents and automobile deaths. The number of adverse drug reactions is slated to increase as more medications become available in the market, and as more healthcare providers implement drug treatment plans that consist of more than four prescription medications.
The World Health Organization (WHO) defines an adverse reaction as “[a] response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function.”
Unfortunately, many medications are prescribed without determining how a patient’s genetic profile influences the assimilation and metabolism of medications. And while some side effects are a challenge to avoid, some ADRs are the result of drug treatment plans that are not well-suited for an individual patient.
Pharmacogenetic testing provides patients and providers with a profile of genetic variances that will assist in designing a treatment plan that will reduce the occurrence of ADRs. When providers have a better understanding of how a patient’s genetic profile may interact with specific medications, a more effective drug treatment plan can be set in motion.